Greg Friberg

Orbital Therapeutics

Ron Philip

Orbital Therapeutics has appointed Ron Philip as chief executive officer. Philip, who has been appointed to the company’s board of directors, has over 30 years of biopharma leadership experience. He was most recently chief executive officer of Spark Therapeutics and previously spent a decade at Pfizer and Wyeth, where he held several roles.

Tiziana Life Sciences

Ivor Elrifi

Tiziana Life Sciences has appointed Ivor Elrifi as chief executive officer. Elrifi brings extensive experience to the role, having most recently served as the global head of the Patent Group at Cooley. Prior to this, he was the global head of patents at Mintz Levin. Elrifi has counselled companies in industries including pharma, biotech and life sciences.

GH Research

Velichka Valcheva

GH Research has appointed Velichka Valcheva as chief executive officer. Valcheva has more than 20 years of industry experience and most recently served as GH Research’s chief medical officer. Prior to joining the company last year, Valcheva was vice president and head of medical affairs international at Albireo, and held roles at Ipsen and Sanofi.

Worldwide Clinical Trials

Tracey Marantal

Worldwide Clinical Trials has appointed Tracey Marantal as president of its oncology business unit. Marantal has over two decades of clinical operations, sponsor and supplier experience, and was most recently vice president of clinical operations at Zai Laboratory. Prior to this, she held leadership roles at Genentech/Roche, including oncology therapeutics area lead.

AAX Biotech

Patrik Strömberg

AAX Biotech has appointed Patrik Strömberg to its board of directors. Strömberg has over two decades of industry experience and is chief executive officer at AnaCardio. He previously served in a variety of roles at Sobi, most recently as vice president, external innovation, search and evaluation, and has also held roles at AstraZeneca and Biovitrum.

PureTech Health

Michele Holcomb

PureTech Health has appointed Michele Holcomb to its board of directors as an independent non-executive director. Holcomb brings more than 30 years of healthcare experience to the position. She was previously executive vice president, chief strategy and business development officer at Cardinal Health, and held multiple roles at Teva Pharmaceuticals.

DiogenX

Eleanor Ramos

DiogenX has appointed Eleanor Ramos as an independent board member. Ramos was recently chief medical officer at Provention Bio and previously held chief medical officer roles at several biotech companies, including Global Blood Therapeutics, Theraclone Sciences and ZymoGenetics. Ramos is currently a member of the scientific advisory board at EpiVax Oncology.

Structure Therapeutics

Ashley Hall

Structure Therapeutics has appointed Ashley Hall as chief development officer. Hall has extensive industry experience and joins Structure from Reneo Pharmaceuticals, where she served as chief development officer. Prior to this, Hall was chief development officer and head of global regulatory affairs at Esperion Therapeutics, and held roles at Amgen and MedImmune.